• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Science | Nature | Cell | View More
    Natural Products
    Dihydroberberine
    Information
    CAS No. 483-15-8 Price $188 / 20mg
    Catalog No.CFN90431Purity>=98%
    Molecular Weight337.36Type of CompoundAlkaloids
    FormulaC20H19NO4Physical DescriptionPowder
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    Citing Use of our Products
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
    Size /Price /Stock 10 mM * 1 mL in DMSO / $67.5 / In-stock
    Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
    Our products had been exported to the following research institutions and universities, And still growing.
  • Universitas Airlangga (Indonesia)
  • University of Wisconsin-Madison (USA)
  • Kazusa DNA Research Institute (Japan)
  • Charles University in Prague (Czech Republic)
  • Sanford Burnham Medical Researc... (USA)
  • Donald Danforth Plant Science C... (USA)
  • Centralised Purchases Unit (CPU... (India)
  • Technical University of Denmark (Denmark)
  • Georgia Institute of Technology (USA)
  • Universidade Federal de Pernamb... (Brazil)
  • Wroclaw Medical University (Poland)
  • More...
  • Package
    Featured Products
    Nodakenin

    Catalog No: CFN90232
    CAS No: 495-31-8
    Price: $138/20mg
    Mulberrofuran H

    Catalog No: CFN92414
    CAS No: 89199-99-5
    Price: $533/5mg
    Isochlorogenic acid C

    Catalog No: CFN99120
    CAS No: 32451-88-0
    Price: $100/20mg
    Kaempferol-3-O-galactoside

    Catalog No: CFN92079
    CAS No: 23627-87-4
    Price: $298/5mg
    Butyrospermol

    Catalog No: CFN92376
    CAS No: 472-28-6
    Price: $388/5mg
    Ganoderol B

    Catalog No: CFN99064
    CAS No: 104700-96-1
    Price: $368/5mg
    Ginsenoside Rk2

    Catalog No: CFN92818
    CAS No: 364779-14-6
    Price: $318/5mg
    Related Screening Libraries
    Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
    10 mM * 1 mL in DMSO / Inquiry / In-stock
    Related Libraries
  • Antibacterial Compound Library
  • Anti-hyperlipidemic Compound Library
  • Anti-insulin resistance Compound Library
  • Antiarrhythmic Compound Library
  • Alkaloids Compound Library
  • AMPK Inhibitor Library
  • Biological Activity
    Description: Dihydroberberine has anti-tumor activity. It also improves in vivo efficacy in terms of counteracting increased adiposity, tissue triglyceride accumulation, and insulin resistance in high-fat-fed rodents, thus is potential therapeutic reagents for type 2 diabetes treatment.
    Targets: AMPK
    In vitro:
    Arch Pharm Res. 1997 Oct;20(5):476-9.
    Studies on the synthesis andin vitro anti-tumor activity of dihydroberberine derivatives.[Pubmed: 18982493]

    METHODS AND RESULTS:
    Three types of Dihydroberberine derivatives such as spirobenzylisoquinoline, benzindenoazepine and cyclopropanated quinolizine species were synthesized from Dihydroberberine for the investigation on their anti-tumor activity.
    CONCLUSIONS:
    Among them, cyclopropanated quinolizine species were more effective than spirobenzylisoquinoline and benzindenoazepine against P-388 and L-1210 leukemia cell.
    In vivo:
    Diabetes. 2008 May;57(5):1414-8.
    Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action.[Pubmed: 18285556]
    Berberine (BBR) activates AMP-activated protein kinase (AMPK) and improves insulin sensitivity in rodent models of insulin resistance. We investigated the mechanism of activation of AMPK by BBR and explored whether derivatization of BBR could improve its in vivo efficacy.
    METHODS AND RESULTS:
    AMPK phosphorylation was examined in L6 myotubes and LKB1(-/-) cells, with or without the Ca(2+)/calmodulin-dependent protein kinase kinase (CAMKK) inhibitor STO-609. Oxygen consumption was measured in L6 myotubes and isolated muscle mitochondria. The effect of a BBR derivative, Dihydroberberine (dhBBR), on adiposity and glucose metabolism was examined in rodents fed a high-fat diet. We have made the following novel observations: 1) BBR dose-dependently inhibited respiration in L6 myotubes and muscle mitochondria, through a specific effect on respiratory complex I, similar to that observed with metformin and rosiglitazone; 2) activation of AMPK by BBR did not rely on the activity of either LKB1 or CAMKKbeta, consistent with major regulation at the level of the AMPK phosphatase; and 3) a novel BBR derivative, dhBBR, was identified that displayed improved in vivo efficacy in terms of counteracting increased adiposity, tissue triglyceride accumulation, and insulin resistance in high-fat-fed rodents. This effect is likely due to enhanced oral bioavailability.
    CONCLUSIONS:
    Complex I of the respiratory chain represents a major target for compounds that improve whole-body insulin sensitivity through increased AMPK activity. The identification of a novel derivative of BBR with improved in vivo efficacy highlights the potential importance of BBR as a novel therapy for the treatment of type 2 diabetes.
    Dihydroberberine Description
    Source: The tubers of Corydalis decumbens (Thunb.) Pers.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds
    Gypenoside XVII

    Catalog No: CFN90193
    CAS No: 80321-69-3
    Price: $148/20mg
    4-O-Feruloylquinic acid

    Catalog No: CFN92392
    CAS No: 2613-86-7
    Price: $448/5mg
    (-)-Gallocatechin

    Catalog No: CFN99137
    CAS No: 3371-27-5
    Price: $178/20mg
    Kobusin

    Catalog No: CFN89280
    CAS No: 36150-23-9
    Price: $318/10mg
    Isoformononetin

    Catalog No: CFN95024
    CAS No: 486-63-5
    Price: $288/5mg
    Lanceolarin

    Catalog No: CFN95166
    CAS No: 15914-68-8
    Price: $318/5mg
    Withaferin A

    Catalog No: CFN91895
    CAS No: 5119-48-2
    Price: $318/10 mg
    Naringin 4'-glucoside

    Catalog No: CFN95014
    CAS No: 17257-21-5
    Price: $338/5mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 2.9642 mL 14.821 mL 29.6419 mL 59.2839 mL 74.1048 mL
    5 mM 0.5928 mL 2.9642 mL 5.9284 mL 11.8568 mL 14.821 mL
    10 mM 0.2964 mL 1.4821 mL 2.9642 mL 5.9284 mL 7.4105 mL
    50 mM 0.0593 mL 0.2964 mL 0.5928 mL 1.1857 mL 1.4821 mL
    100 mM 0.0296 mL 0.1482 mL 0.2964 mL 0.5928 mL 0.741 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Protocol
    Animal Research:
    Bioorg Med Chem. 2010 Aug 15;18(16):5915-24.
    8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models.[Pubmed: 20663675]
    The clinical use of the natural alkaloid berberine (BBR) as an antidiabetic reagent is limited by its poor bioavailability. Our previous work demonstrated that Dihydroberberine (dhBBR) has enhanced bioavailability and in vivo efficacy compared with berberine.
    METHODS AND RESULTS:
    Here we synthesized the 8,8-dimethylDihydroberberine (Di-Me) with improved stability, and bioavailability over dhBBR. Similar to BBR and dhBBR, Di-Me inhibited mitochondria respiration, increased AMP:ATP ratio, activated AMPK and stimulated glucose uptake in L6 myotubes. In diet-induced obese (DIO) mice, Di-Me counteracted the increased adiposity, tissue triglyceride accumulation and insulin resistance, and improved glucose tolerance at a dosage of 15mg/kg. Administered to db/db mice with a dosage of 50mg/kg, Di-Me effectively reduced random fed and fasting blood glucose, improved glucose tolerance, alleviated insulin resistance and reduced plasma triglycerides, with better efficacy than dhBBR at the same dosage.
    CONCLUSIONS:
    Our work highlights the importance of Dihydroberberine analogs as potential therapeutic reagents for type 2 diabetes treatment.